The Efficacy of Everolimus and Sunitinib in Patients with Sporadic or Germline Mutated Metastatic Pancreatic Neuroendocrine Tumors

被引：0
作者：
Nunez, J. E. [1 ]
Donadio, M. [2 ]
Rocha Filho, D. [3 ]
Rego, J. [4 ]
Barros, M. [2 ]
Formiga, M. N. [2 ]
Lopez, R. [5 ]
Riechelmann, R. [2 ]
机构：
[1] AC Camargo Canc Ctr, Inst Canc Estado Sao Paulo, Sao Paulo, Brazil
[2] AC Camargo Canc Ctr, Sao Paulo, Brazil
[3] Hosp Univ Walter Cantidio, Fortaleza, Ceara, Brazil
[4] Hosp Univ Onofre Lopes, Natal, RN, Brazil
[5] Inst Canc Estado Sao Paulo, Sao Paulo, Brazil
来源：
NEUROENDOCRINOLOGY | 2019年 / 108卷
关键词：
neuroendocrine; pancreatic net; metastatic net; everolimus; sunitinib; men1; multiple endocrine neoplasia type 1; vhl; von-hippel-lindau; germline mutation; sporadic;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
I11
引用
收藏
页码：176 / 176
页数：1
相关论文
共 50 条
  • [21] Evaluation of Everolimus (EVE) in Patients with Metastatic Lung Neuroendocrine Tumors
    Kuznetsova, A.
    Gorbunova, V
    Orel, N.
    Emelianova, G.
    Markovich, A.
    Kolomeytceva, A.
    Fedenko, A.
    NEUROENDOCRINOLOGY, 2018, 106 : 215 - 215
  • [22] Metastatic Pancreatic Neuroendocrine Tumors with Ectopic Cushing Syndrome: Could Everolimus Be a Safe Therapeutic Option?
    Davi, M., V
    Cingarlini, S.
    Butturini, G.
    Capelli, P.
    Scarpa, A.
    Francia, G.
    NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 295 - 295
  • [23] Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison
    Ishak, K. Jack
    Rael, Michael
    Hicks, Meagen
    Mittal, Sangeeta
    Eatock, Martin
    Valle, Juan W.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2018, 7 (10) : 947 - 958
  • [24] The Efficacy of a Lower Dose of Everolimus in Patients with Advanced Neuroendocrine Tumors
    Taboada, Rodrigo G.
    Brito, Angelo B.
    Silva, Ana Luiza
    Weschenfelder, Rui F.
    Riechelmann, Rachel P.
    CANCERS, 2024, 16 (22)
  • [25] The Efficacy and Safety of Sunitinib in Patients with Advanced Well Differentiated Pancreatic Neuroendocrine Tumors: Focus on Response Rate
    Raymond, E.
    Kulke, M. H.
    Qin, S.
    Yu, X.
    Schenker, M.
    Cubillo, A.
    Lou, W.
    Tomasek, J.
    This-Evensen, E.
    Fernandez, K.
    Rosbrook, B.
    Fazio, N.
    NEUROENDOCRINOLOGY, 2017, 105 : 225 - 225
  • [26] Efficacy and Safety of Sunitinib as Long-Term Treatment in Japanese Patients with Advanced Pancreatic Neuroendocrine Tumors
    Lee, L.
    Ueda, K.
    Fujiyama, T.
    Tachibana, Y.
    Yasunaga, K.
    Miki, M.
    Kawabe, K.
    Ito, T.
    NEUROENDOCRINOLOGY, 2016, 103 : 69 - 69
  • [27] Long-Term Everolimus Treatment of Patients with Pancreatic Neuroendocrine Tumors
    Wolin, Edward M.
    CHEMOTHERAPY, 2014, 60 (03) : 143 - 150
  • [28] Cost-Utility of Sunitinib (SU) for Treatment of Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET) in Scotland and Wales
    Johns, A.
    Eatock, M.
    Johal, S.
    NEUROENDOCRINOLOGY, 2012, 96 : 38 - 38
  • [29] Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study
    Rinzivillo, Maria
    Fazio, Nicola
    Pusceddu, Sara
    Spallanzani, Andrea
    Ibrahim, Toni
    Campana, Davide
    Marconicini, Riccardo
    Partelli, Stefano
    Badalamenti, Giuseppe
    Brizzi, Maria Pia
    Catena, Laura
    Schinzari, Giovanni
    Carnaghi, Carlo
    Berardi, Rossana
    Faggiano, Antongiulio
    Antonuzzo, Lorenzo
    Spada, Francesca
    Gritti, Sara
    Femia, Daniela
    Gelsomino, Fabio
    Bongiovanni, Alberto
    Ricci, Sergio
    Brighi, Nicole
    Falconi, Massimo
    Delle Fave, Gianfranco
    Panzuto, Francesco
    PANCREATOLOGY, 2018, 18 (02) : 198 - 203
  • [30] Efficacy and Safety of Everolimus plus Somatostatin Analogues in Patients with Neuroendocrine Tumors
    Ge, Wenhao
    Zhou, Dongkai
    Zhu, Lijun
    Song, Wei
    Wang, Weilin
    JOURNAL OF CANCER, 2018, 9 (24): : 4783 - 4790
12345